Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (201-210 of 289) with videos related to

Pageof 29
Sort By:
Clinical Lung Cancer|March 19, 2020
Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical TrialDavid E Gerber, Heidi A Hamann, Claudia Chavez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2024
Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable PopulationsSheena Bhalla, Vijaya Natchimuthu, Jessica L Lee, et al.
Oncology|December 18, 2019
Unique Patterns of Distant Metastases in HPV-Positive Head and Neck CancerRuth Sacks, Jennie Y Law, Hong Zhu, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer modelsRyan R Kowash, Manoj Sabnani, Laura T Gray, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 11, 2025
Protected Time, Resources, and Expectations for Academic Oncology Clinical Research PhysiciansDavid E Gerber, Nikhil I Khushalani, Ang Gao, et al.
Cancer Medicine|August 2, 2025
Implementation of a Patient Navigation Program to Support Representative Participation in Cancer Clinical TrialsSukh Makhnoon, Fabian Robles, Jessica L Lee, et al.
Journal of Surgical Oncology|March 28, 2017
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancerMuhammad Shaalan Beg, Xiumei Huang, Molly A Silvers, et al.
International Journal of Radiation Oncology, Biology, Physics|August 15, 2024
Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief ReportYuanyuan Zhang, Puneeth Iyengar, Steven Montalvo, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2015
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancerDavid E Gerber, David A Boothman, Farjana J Fattah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung CancerRamaswamy Govindan, Sumithra J Mandrekar, David E Gerber, et al.
Pageof 29

Showing results (201-210 of 289) with videos related to

Sort By:
Pageof 29
Clinical Lung Cancer|March 19, 2020
Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical TrialDavid E Gerber, Heidi A Hamann, Claudia Chavez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2024
Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable PopulationsSheena Bhalla, Vijaya Natchimuthu, Jessica L Lee, et al.
Oncology|December 18, 2019
Unique Patterns of Distant Metastases in HPV-Positive Head and Neck CancerRuth Sacks, Jennie Y Law, Hong Zhu, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer modelsRyan R Kowash, Manoj Sabnani, Laura T Gray, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 11, 2025
Protected Time, Resources, and Expectations for Academic Oncology Clinical Research PhysiciansDavid E Gerber, Nikhil I Khushalani, Ang Gao, et al.
Cancer Medicine|August 2, 2025
Implementation of a Patient Navigation Program to Support Representative Participation in Cancer Clinical TrialsSukh Makhnoon, Fabian Robles, Jessica L Lee, et al.
Journal of Surgical Oncology|March 28, 2017
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancerMuhammad Shaalan Beg, Xiumei Huang, Molly A Silvers, et al.
International Journal of Radiation Oncology, Biology, Physics|August 15, 2024
Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief ReportYuanyuan Zhang, Puneeth Iyengar, Steven Montalvo, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2015
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancerDavid E Gerber, David A Boothman, Farjana J Fattah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung CancerRamaswamy Govindan, Sumithra J Mandrekar, David E Gerber, et al.
Pageof 29